Advair Diskus & Asthma therapy

Advair Diskus belongs to a group of glucocorticosteroids (GCS), which are synthetic drugs (analogs of endogenous hormones produced by the adrenal cortex) characterized by anti-inflammatory, desensitizing, immunosuppressive, anti-shock and toxic effect. GCS feature diverse effect, many elements of which are not fully understood. At present, the studies research questions of their systemic bioavailability, side effects associated with long-term use and effects of treatment on related diseases.

Despite advances in treatment of asthma, the issue is still relevant. A selection of drugs to fight asthma is rather vast. Though, the results often fail to satisfy both doctors and patients.

Basic anti-inflammatory therapy used to be a proven method. Recently, researchers offered patients a new means, called Advair Diskus.

In accordance with guidelines and standards, the choice of drugs and doses depends on the disease severity.

Advair Diskus is known to be used since 1993. Currently, doctors prescribe dosed aerosol and powder inhalers: low (100-250mkg), medium (250-500mkg) and high daily doses (more 500mkg).

A combination of inhaled corticosteroids and long-acting β2-agonists is top-priority.

Availability of Advair Diskus facilitates individualized treatment for a specific period of disease. This is especially true in patients with "hormone-dependent" asthma (sterjoid dependent ast.). This severe form of asthma is characterized by frequent exacerbations and complications. To prevent negative consequences, doctors prescribe a long-term (within months) intake of Advair Diskus. Considering possible side effects, one would like to use a smaller dose of corticosteroids.

Here, the use of nebulizers turns extremely relevant. However, this also fails to fundamentally solve problems of treatment.

Good results of Advair Diskus in treatment of acute exacerbations of asthma of moderate severity are based both on psychotherapy and fluticasone propionate influence on β2-adrenergic receptors of the respiratory tract. The drug succeeds to promote development of β2-adrenergic receptors, eliminate «diown»-effect and increase sensitivity to β2-agonists. Synergism of inhaled corticosteroids and prolonged β2-agonists is proved at molecular, cellular and receptor levels.

Thus, aerosol inhaler Advair Diskus is an efficient means to fight asthma.